Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Buys NextGen's Electrophoresis Business

NEW YORK (GenomeWeb News) – NextGen Sciences said today that it has sold its electrophoresis business to Sigma-Aldrich for an undisclosed sum.

The Ann Arbor, Mich.-based company said the deal is part of its strategic realignment plan to pare back its operations and focus on its biomarker services.

Under this agreement, Sigma-Aldrich has acquired NextGen's automated gel casting unit, the a2DEoptimizer, and its large format pre-cast gels for a cash payment and royalties based on revenues over three years.

Sigma-Aldrich will focus its efforts primarily on supplying the optigels to customers in Europe and North America.

NextGen said in April 2008 that it would seek to divest or wind down its software and instrumentation UK-based businesses and focus all of its resources on biomarker services, which include discovery, assay development, and testing.

NextGen licensed its expressionfactory, expressionworkstation, and the orchestratorIMS software suite to eXeTek, a NextGen spinout company, in December.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.